ERBB2 and lung adenocarcinoma: Hence, our findings provide a therapeutic reference for patients with HER2-positive lung adenocarcinoma, not only by reducing the dosage of cisplatin, which leads to fewer toxic side effects of chemotherapy but also by reducing the financial burden.